Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-12-30 Sale | 2025-01-02 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 29,846 | $25.54 | $762,174 | 10,656,172 (Indirect) | View |
| 2024-12-26 Sale | 2024-12-30 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 74,910 | $25.98 | $1,945,918 | 10,686,018 (Indirect) | View |
| 2024-12-20 Sale | 2024-12-26 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 91,068 | $25.58 | $2,329,520 | 10,760,928 (Indirect) | View |
| 2024-12-18 Sale | 2024-12-20 4:25 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 157,234 | $25.86 | $4,066,714 | 10,851,996 (Indirect) | View |
| 2024-12-16 Sale | 2024-12-18 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 115,480 | $25.95 | $2,996,156 | 11,009,230 (Indirect) | View |
| 2024-12-12 Sale | 2024-12-16 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 191,762 | $25.34 | $4,859,875 | 11,124,710 (Indirect) | View |
| 2024-12-10 Sale | 2024-12-12 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 462,288 | $25.4 | $11,740,618 | 11,316,472 (Indirect) | View |
| 2024-11-15 Sale | 2024-11-19 4:15 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 41,803 | $25.07 | $1,047,876 | 11,778,760 (Indirect) | View |
| 2024-11-13 Sale | 2024-11-15 4:36 pm | NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner | 10,898 | $25.01 | $272,511 | 11,820,563 (Indirect) | View |
| 2024-10-01 Sale | 2024-10-01 5:23 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 45,000 | $15.72 | $707,400 | 168,073 (Direct) | View |
| 2024-09-26 Purchase | 2024-09-30 5:22 pm | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer | 1,104 | $15.7 | $17,333 | 1,104 (Direct) | View |
| 2024-08-20 Purchase | 2024-08-22 4:30 pm | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 5,000 | $16.27 | $81,350 | 818,563 (Indirect Direct) | View |
| 2024-06-20 Purchase | 2024-06-24 08:30 am | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 5,000 | $17.26 | $86,309 | 813,563 (Indirect Direct) | View |
| 2024-03-26 Purchase | 2024-03-28 4:30 pm | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director | 8,429 | $21.5 | $181,224 | 6,809,429 (Indirect) | View |
| 2024-03-26 Sale | 2024-03-27 4:30 pm | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 190,476 | $21.5 | $4,095,234 | 970,229 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-01-06 Option Award | 2025-01-08 6:09 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director | 39,460 | $0 | 39,460 (Direct) | View |
| 2025-01-06 Option Award | 2025-01-08 6:08 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director | 39,460 | $0 | 39,460 (Direct) | View |
| 2025-01-06 Option Award | 2025-01-08 6:03 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director | 39,460 | $0 | 39,460 (Direct) | View |
| 2025-01-06 Option Award | 2025-01-08 5:58 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director | 39,460 | $0 | 39,460 (Direct) | View |
| 2025-01-06 Option Award | 2025-01-08 5:57 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director | 39,460 | $0 | 64,338 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:21 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 15,000 | $0 | 15,000 (Direct) | View |
| 2025-01-06 Option Award | 2025-01-07 5:21 pm | N/A 2035-01-06 | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 793,996 | $0 | 793,996 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:21 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 34,000 | $0 | 34,000 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:15 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer | 14,000 | $0 | 15,104 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:12 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer | 43,000 | $0 | 43,000 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:10 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 44,000 | $0 | 44,000 (Direct) | View |
| 2025-01-07 Option Award | 2025-01-07 5:08 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 38,000 | $0 | 38,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:57 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer | 250,000 | $0 | 250,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:56 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 80,000 | $0 | 80,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:54 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:53 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer | 220,000 | $0 | 220,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:51 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2025-01-02 Option Award | 2025-01-06 5:48 pm | N/A 2035-01-02 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2024-10-09 Gift | 2024-10-11 5:01 pm | 2022-12-22 2027-11-23 | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer | 15,000 | $11.5 | 85,000 (Direct) | View |
| 2024-09-27 Exercise | 2024-10-01 5:23 pm | N/A 2031-07-06 | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer | 45,000 | $0 | 168,073 (Direct) | View |
| 2024-07-17 Option Award | 2024-07-19 4:31 pm | N/A 2034-07-17 | NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director | 72,500 | $0 | 72,500 (Direct) | View |
Ownership | 2024-05-03 4:15 pm | N/A 2033-08-14 | NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer | 0 | $0 | 945,598 (Direct) | View |
| 2024-04-01 Option Award | 2024-04-02 4:30 pm | N/A 2034-04-01 | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer | 250,000 | $0 | 250,000 (Direct) | View |
| 2024-03-26 Tax Withholding | 2024-03-27 4:30 pm | N/A N/A | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 11,197 | $22.72 | 970,229 (Indirect) | View |
| 2024-03-26 Exercise | 2024-03-27 4:30 pm | N/A 2031-07-06 | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer | 201,673 | $0 | 970,229 (Indirect) | View |